arrow
Y

Yoshihide Ueda

kakogawa central city hospital
H指数:31
被引数:6,219

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma

在初始使用阿替利珠单抗/贝伐珠单抗控制疾病后,疾病进展时基于消融的挽救策略在肝细胞癌中的应用

2026-05-110
PRE
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

不可切除性肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后出血事件的临床特征、预测因素及抗血栓治疗的影响

2026-04-210
PRE
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

2026-04-100
PRE
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

淋巴细胞-单核细胞比值预测接受度鲁单单抗联合曲美单抗治疗的HCC患者的生存情况

2026-02-260
PRE
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease

日本过去二十年间肝细胞癌治疗结果的演变:早期病毒性疾病的改善

2025-11-010
OA
Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis

淋巴细胞-单核细胞比率预测接受度鲁单单抗联合曲美木单抗治疗不可切除性肝细胞癌患者的生存情况:一项多中心分析

2025-11-011
OA
Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan

日本模型终末期肝病模型(Model for End-Stage Liver Disease, MELD)评分分配政策下,成人慢性终末期肝病候选者在等待 deceased donor liver transplantation( deceased donor liver transplantation)过程中的等待名单死亡率和移植概率的当前状况。

2025-08-140
PRE
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

达鲁瓦鲁单抗联合特雷美鲁单抗在不可切除肝细胞癌老年患者中的安全性与有效性:一项多中心分析

2025-08-060
PRE
Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort study
2024-08-020
OAAI
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

肿瘤形态与阿特珠单抗联合贝伐单抗治疗晚期肝癌疗效的关系

2024-02-144
PRE
Autoimmune hepatitis cholestatic variant syndromes recurrence following liver transplantation affects graft and patient survival in an international multicentre cohort
2024-02-010
PRE
Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis
2023-06-137
OAAI